《生物制品价格竞争与创新法案》下的战略考量。
Strategic considerations under the Biologics Price Competition and Innovation Act.
出版信息
Expert Opin Ther Pat. 2013 Aug;23(8):915-8. doi: 10.1517/13543776.2013.813935. Epub 2013 Jul 6.
PMID:23829693
Abstract
The Biologics Price Competition and Innovation Act provides a pathway for regulatory approval of generic drugs and the associated patent challenge. This article reviews strategic considerations during the patent litigation and injunction phases. Considerations during the initial patent litigation phase include when and whether to exchange a paragraph k application and the listing and exchange of patent information during the volley phase.
摘要
《生物制品价格竞争与创新法案》为仿制药的监管批准和相关专利挑战提供了途径。本文回顾了专利诉讼和禁制令阶段的战略考虑因素。在初始专利诉讼阶段需要考虑的因素包括何时以及是否提出 Paragraph k 申请，以及在交锋阶段列出和交换专利信息。
相似文献
1
Strategic considerations under the Biologics Price Competition and Innovation Act.《生物制品价格竞争与创新法案》下的战略考量。
Expert Opin Ther Pat. 2013 Aug;23(8):915-8. doi: 10.1517/13543776.2013.813935. Epub 2013 Jul 6.
2
3
4
Biosimilars in the United States: Emerging Issues in Litigation.美国的生物类似药：诉讼中的新问题。
BioDrugs. 2017 Jun;31(3):189-205. doi: 10.1007/s40259-017-0216-7.
5
Implementation of the biosimilar pathway: economic and policy issues.生物类似药途径的实施：经济与政策问题
Seton Hall Law Rev. 2011;41(2):511-57.
6
Biosimilars: impact of differences with Hatch-Waxman.生物类似药：与哈奇-沃克斯曼法案差异的影响
Pharm Pat Anal. 2013 Jan;2(1):29-37. doi: 10.4155/ppa.12.77.
7
8
Are biosimilars patentable?生物类似药可获专利吗？
Expert Opin Ther Pat. 2016 Aug;26(8):871-5. doi: 10.1080/13543776.2016.1193156. Epub 2016 Jun 23.
9
An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.2009年《生物制品价格竞争与创新法案》的非官方立法史。
Food Drug Law J. 2010;65(4):671-818, ii.
Zotero 插件